Cambridge, UK – For the first time, the developmental stages of the deadliest human malaria parasite have been mapped in high resolution, allowing researchers to understand this ever-adapting adversary in more detail than previously possible. The study, published today (2 May) in Science, details the critical developmental stages of the...
Latest News
WILMINGTON, Del. – AstraZeneca Pharmaceuticals LP and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment or...
Tokyo, Japan and Basking Ridge, NJ – Positive topline results from a planned interim analysis of the DESTINY-Breast09 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to taxane, trastuzumab and pertuzumab (THP) as a first-line treatment for patients...
TOKYO & MUNICH & BASKING RIDGE, N.J. – Detailed primary results from the positive, pivotal DESTINY-Lung01 phase 2 trial of ENHERTU® (trastuzumab deruxtecan), the Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca HER2 directed antibody drug conjugate (ADC), showed a robust and durable tumor response in previously-treated patients with...
Chapel Hill, NC – Throughout the day and night, cerebrospinal fluid (CSF) pulses through small fluid-filled channels surrounding blood vessels in the brain, called perivascular spaces, to flush out neuroinflammation and other neurological waste. A disruption to this vital process can lead to neurological dysfunction, cognitive decline, or developmental delays....
Employing “electronic nose” (eNose) technology early during treatment can accurately identify patients with advanced non-small cell lung cancer (NSCLC) who respond to immunotherapy, according to research published in Lung Cancer. The technology can allow for noninvasive, low-cost identification of responders early on, which could save patients from ineffective treatment, “thereby preventing...
BOSTON, Mass. — Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced that the first patient has been dosed in the company’s Phase 1/2 clinical trial of EN-374. EN-374 is an in vivo hematopoietic stem cell (HSC)-directed gene insertion therapy for...
PARIS, France — Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced database lock of its Phase 2 study of EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab), for...
PARIS – ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, today announces that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with a...
PARIS – ENTEROME SA, a clinical stage biopharmaceutical company developing novel therapeutics based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, is pleased to announce the appointment of Anne Dagallier, PhD, as Chief Business Officer (CBO). Dr Dagallier brings over 22 years of...